Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome

Aim This study sought to clarify the usefulness of lenvatinib for patients with unresectable hepatocellular carcinoma (HCC). Methods The subjects were 69 patients with HCC receiving lenvatinib; the median age was 73 years, and 14 and 67 patients had been previously treated with regorafenib and/or so...

Ausführliche Beschreibung